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and the sensitive impairment of quality of life signiﬁcantly con-
tribute to the high socioeconomic burden of AD.
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BELGIAN DRUG UTILISATION STUDY OF ELIDEL® IN
ROUTINE PRACTICE IN ATOPIC DERMATITIS
Lecomte P1, Lambert J2, Degreef H3, Lesaffre E4, De Backer M1
1Novartis Pharmaceuticals,Vilvoorde, Belgium, 2UZ-Antwerpen,
Antwerpen, Belgium, 3UZ-St Rafaël, Leuven, Belgium, 4Biostatistical
Centre KULeuven, Leuven, Belgium
OBJECTIVES: To assess the impacts of Elidel® (pimecrolimus)
cream 1% usage, in routine Belgian clinical practice in patients
with mild to moderate atopic dermatitis, in terms of: pime-
crolimus drug consumption; use of topical corticosteroids;
quality of life; and safety. METHODS: An open-label, single
arm, observational, multicenter study with one year follow-up
to cover the seasonality of atopic dermatitis. Yearly pime-
crolimus drug consumption was estimated based on the number
and quantity of delivered prescriptions and on the number of
unused or partially used tubes left at the end of the study. Topical
corticosteroid use was assessed by a steroid usage questionnaire
and the delivered topical corticosteroid prescriptions. Quality of
life was gauged using validated disease speciﬁc instruments, i.e.
the Parents’Index Quality of Life-Atopic Dermatitis (PIQoL-AD)
or the Quality of Life Index-Atopic Dermatitis (QoLIAD),
depending on patient’s age. All adverse events were recorded.
RESULTS: A total of 416 patients were enrolled from 49 study
centers geographically spread over Belgium. For patients who
completed this 12 months study, the mean (SD) amount of pre-
scribed pimecrolimus cream 1% per patient was 120.8 (117.0)
gram per year, with an estimated consumption of 104.4 (117.6)
gram per year. Topical corticosteroids were used before the study
in 81.7% of the population. At the end of study 83.3% of them
stated that they were using less topical corticosteroids when
pimecrolimus is part of their treatment regimen. Mean (SD)
improvements versus baseline in PIQoL-AD and QoLIAD scores
were 34.5% (84.3%) and 31.2% (70.8%), respectively. Median
(IQR) improvements were 50.0% (12.5%–85.7%) and 46.4%
(0.0%–85.0%), respectively. Pimecrolimus also showed good
tolerability proﬁle. CONCLUSIONS: This observational study
showed favorable pimecrolimus proﬁle in routine practice
reﬂected by relatively small amount of drug used, corticosteroid
sparing effect, improvement in quality of life, and good 
tolerability.
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Generic Quality of Life (QoL) instruments are useful to compare
different populations. However these instruments could be crit-
icized for having some drawbacks, and disease-speciﬁc instru-
ments could be preferred to measure those aspects of wellbeing
inﬂuenced by a speciﬁc disease and to effectively measure health
changes over the time. OBJECTIVE: We tested convergent valid-
ity and sensitivity to change over time of a generic and disease-
speciﬁc pediatric questionnaires to evaluate wellbeing in children
with Atopic Dermatitis (AD), a very frequent, chronic and dis-
abling disease. METHODS: Data from the Costi-&-Outcomes-
in-Dermatite-Atopica (CODA) naturalistic, prospective Cost-Of-
Illness study, involving moderate and severe AD patients, were
used. Patients aged 5–16 y.o. and/or their caregivers completed
twice (at ﬂare-up and after 2 months) the KINDL (children-
reported version: KINDL-C, parent-reported version: KINDL-P;
scores = 0–100, higher score = higher QoL) and CDLQI (Chil-
dren’s-Dermatology-Life-Quality-Index, with scores = 0–30,
higher score = lower QoL). Patients’ clinical status was evalu-
ated with the SCORAD index (SCORing-Atopic-Dermatitis,
possible score = 0–100, higher score = higher severity). We tested
convergent validity by investigating correlations between QoL
instruments; sensitivity to change over time was tested with
paired students’ t tests, Standardized Response Mean (SRM),
Effect Size (EF). RESULTS: Pediatric patients were 66, 43.9%
male, median age = 8.8 y.o., median SCORAD at enrolment =
41.5 (3.0–85.0). CDLQI signiﬁcantly correlated with KINDL-P
(Spearman’s r = −0.44 p = 0.001) and KINDL-C (r = −0.36 p =
0.008), KINDL-P sensitively correlated with KINDL-C (r = 0.67
p < 0.0001). At follow-up clinical severity signiﬁcantly decreased
(Student’s paired t test, p < 0.0001). Patients reported signiﬁcant
lower scores of CDLQI (Student’s paired t test, p < 0.05), while
no statistical change was found with KINDL-P and KINDL-C.
SRM and ES were moderate for CDLQI (SRM = 0.44, ES = 0.41)
and low for KINDL-C (SRM = 0.26, ES = 0.26) and KINDL-P
(SRM = 0.12, ES = 0.11). CONCLUSION: KINDL signiﬁcantly
correlated with CDLQI, anyway sensitivity to change results
were moderate to low. Understanding these properties in QoL
questionnaires is necessary to allow their appropriate use and
interpretation of QoL data.
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Generic instruments such as EQ-5D are useful to compare
quality of life (QoL) of different populations and to include QoL
information in health-economic research. However these instru-
ments could be criticized for having some drawbacks, and
disease-speciﬁc instruments could be more capable to measure
those aspects of wellbeing inﬂuenced by a speciﬁc disease and
could be more sensitive to measure health changes over the time.
OBJECTIVE: We tested convergent validity and sensitivity to
change over time of EQ-5D and the Dermatology-Life-Quality-
Index (DLQI, possible scores = 0–30, higher score = lower QoL)
in Atopic Dermatitis (AD), a very frequent, chronic, sensitively
disabling disease. METHODS: Data from the Costi-&-Out-
comes-in-Dermatite-Atopica (CODA) naturalistic, prospective,
Cost-Of-Illness study, involving moderate and severe AD
patients, were used. Socio-demographic, clinical severity (with
SCORAD, SCORing-Atopic-Dermatitis index, possible score =
0–100, higher score = higher severity), economic and QoL data
were collected. Patients from 16 y.o. self-completed twice (at
ﬂare-up and after 2 months) EQ-5D and DLQI. We tested cor-
relation of EQ-5D indexes with DLQI and sensitivity to change
over time of these indexes with paired Students’ t tests, Stan-
dardized Response Mean (SRM), Effect Size (EF). RESULTS:
Patients were 98, 48% male, median age = 30.5 y.o. (18–77). At
enrolment median SCORAD = 53.0 (18.4–90.0), median EQ-
VAS = 65.0 (0.0–95.0), median utility score from EQ-proﬁle =
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0.69 (−0.24 to 1.00), median DLQI = 10.0 (0.0–30.0). EQ-VAS
and utilities signiﬁcantly correlated with DLQI (Spearman’s coef-
ﬁcient >−0.500, p < 0.0001 in every case). At follow-up
SCORAD signiﬁcantly decreased and patients reported signiﬁ-
cant higher levels of QoL with every score (Student’s paired t
test, p < 0.0001 in every index). SRM (EQ-VAS = 0.85, utility =
0.70, DLQI = 0.89) and ES (EQ-VAS = 0.90, utility = 0.76, DLQI
= 0.81) were signiﬁcant. CONCLUSION: EQ-5D and DLQI are
good to measure QoL related to AD and to evaluate wellbeing
change over time. A routine use of these instruments should be
considered in evaluating consequences of AD and its treatment
on patients’ wellbeing to optimize therapeutic choices.
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Skin problems such as Atopic Dermatitis (AD) cause sensitive
quality of life (QoL) impairment, with major impact on psy-
chosocial state, social relationships and everyday activities.
OBJECTIVE: To evaluate the socioeconomic impact of AD.
METHODS: It was a naturalistic, multicenter, longitudinal,
ambispective (retro-prospective), prevalence-based Cost-Of-
Illness study enrolling adult and pediatric patients with moder-
ate or severe AD and ﬂare-up. Data was on socio-demographic,
clinical severity (with SCORAD, SCORing-Atopic-Dermatitis
index, possible score = 0–100, higher score = higher severity),
economic (direct and indirect costs), intangible costs in terms of
Health-Related-Quality-of-Life (HRQoL), preferences towards
pharmacological treatment. Following results pertain to adult
patients’ HRQoL, evaluated with the disease-speciﬁc DLQI (Der-
matology-Life-Quality-Index, with scores 0–30, higher score =
lower HRQoL) and the generic EQ-5D. RESULTS: A total of 98
valid adult patients (48% male) from 5 Italian dermatological
centres were enrolled; 39.8% patients were 18–27 y.o., 30.6%
were 28–37 y.o., 29.6% were >38 y.o. At enrollment the median
SCORAD was 53.0 (18.4–90.0), the median DLQI was 10.0
(0.0–30.0), the median EQ-VAS (EQ-Visual-Analogue-Scale) 
was 65.0 (0.0–95.0). Concerning the EQ-5D proﬁle, 12.2% of
patients reported moderate problems with “mobility” and
27.6% with “self-care” (nobody reported severe problems),
53.0% moderate/severe problems with “usual activities”, 95.1%
moderate/severe levels of “pain/discomfort”, 65.9% moderate/
severe levels of “anxiety/depression”. After 2 months from enrol-
ment, the SCORAD decreased signiﬁcantly (Wilcoxon-Signed-
Ranks test, p < 0.0001) and patients reported higher levels of
wellbeing (Wilcoxon-Signed-Ranks test for DLQI or EQ-VAS, 
p < 0.0001). Also the EQ-5D proﬁle signiﬁcally got better for
“usual activities” (McNemar test: p < 0.001), “pain/discomfort”
and “anxiety/depression” (McNemar test: p < 0.0001). CON-
CLUSIONS: This is the ﬁrst study evaluating the QoL conse-
quences of AD in Italy. Adults with AD have impaired levels of
HRQoL, worsening during the relapse period. The adoption of
HRQoL instruments can help physicians and decision-makers 
in the adoption of more effective and efﬁcient health care 
technologies.
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OBJECTIVES: Little attention has been paid to determining
whether different language versions of the same patient-reported
outcome (PRO) measure are equivalent and if their use intro-
duces bias into multinational studies in the form of differential
item functioning (DIF). The study was designed to see whether
it is possible to overcome such DIF in the development of PRO
measures. METHODS: Data collected with a draft PRO—the
12-item Quality of Life Index for Children with Atopic Der-
matitis (QoLICAD)—from France, Germany, Italy, The Nether-
lands and USA were analysed. Rasch analyses were applied to
the data from each country to determine item ﬁt and DIF by
culture. Where some but not all items display DIF, it is possible
to treat them as a different item in each country. This procedure
is referred to as “splitting” items. The analysis was then re-run
on the new item sets. RESULTS: Data were available on 691
(52.4%M; mean age 4.4 years) children in the 5 countries. Rasch
analyses applied to the data indicated that, following the removal
of misﬁtting items, there was considerable DIF by country. A
European and separate US QoLICAD were derived. Four items
were deleted and four were split to create a 20-item European
scale that ﬁtted the Rasch model (Chi2 p < 0.002 after bonfer-
roni correction). Five items were deleted before the US scale ﬁtted
the Rasch model (Chi2 p < 0.004 after bonferonni correction).
The European and US data were linked by six common items
allowing pooling of data from an international study. CON-
CLUSIONS: Language adaptations should be conceptually
equivalent to the original. However, DIF by culture may remain.
If data are to be pooled such DIF needs to be assessed and
accounted for. The method illustrated is a suitable way of achiev-
ing this but requires further testing in a clinical trial setting.
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OBJECTIVE: The preferences of patients and their care-givers
should be considered in the development of treatment strategies.
The aim is to establish care-givers’ preferences and their will-
ingness-to-pay (WTP) on different Atopic Dermatitis (AD) treat-
ment options. METHODS: The CODA study was a naturalistic,
multicentre, longitudinal ambispective (retro-prospective),
prevalence based Cost-of-Illness study. Data on patients with
moderate or severe AD enrolled during ﬂare-up were collected.
A discrete-choice-experiment (DCE) was applied to care-givers
of the enrolled children. enrolled patients. The enrolled subjects
had to choose between two different scenarios in 16 pair-wise
comparisons. The following attributes were considered to be
important after interviewing 20 care-givers and 6 physicians: dis-
tribution mode (local-pharmacy vs. hospital-pharmacy), the
delay of The rapeutic-response (4 hours vs. 24 hours vs. 48
hours), duration of therapeutic-response (1 week vs. 4 weeks vs.
8 weeks), long-term side effects (possible vs. no), local side effects
(possible vs. no). In order to obtain the WTP we added cost of
treatment out-of-pocket (€0 vs. €50 vs. €100/month). RESULTS:
The caregivers (98% parents) of 79 valid children ﬁlled in the
